The world of publishing, especially scholarly and academic publishing, isn’t just about putting information on paper and selling it to schools. As information solutions provider John Wiley & Sons knows, it’s really about making data and information available to the people who need it most.
In an statement from earlier today, Wiley announced the acquisition of SimBioSys, a scientific software tool developer that is widely know for facilitating the drug discovery process. This acquisition will pair the proven capabilities of SimBioSys’ research-driven platform with Wiley’s knowledge solutions for researchers and the educational community.
“Wiley has deep roots in top quality chemistry publishing with high-profile international chemistry society partnerships and extensive chemical databases, journals, books and references,” said Steve Miron, Senior Vice President of Wiley’s Global Research business. “By combining our traditional published content and databases with machine learning algorithms, we can support chemists in innovative research as they advance world knowledge.”
“The acquisition of SimBioSys accelerates the development of Wiley Science Solutions, our integrated suite of workflow tools for researchers,” said Dr. Mike Davis, Vice President and Managing Director, Research Innovations “SymBioSys has developed technology that enables the computer to learn organic chemistry. These tools enable chemists working in industry and academia to find new and better ways of synthesizing target compounds, saving them time and money.”